Armata Pharma Q4 loss $9.6M; secures $35M loan at 14%, matures June 2025

Armata Pharmaceuticals, Inc.

Q4 2023 loss from operations $(9.6)M vs $(10.3)M in Q4 2022; cash $13.5M at Dec 31, 2023.
Entered $35M credit agreement with Innoviva SO on March 4, 2024; 14% annual rate, matures June 4, 2025.
Phase 2 diSArm study of AP-SA02 for Staph aureus bacteremia continues dose escalation; Phase 2 Tailwind study of AP-PA02 for NCFB progressing.
Manufacturing facility advanced; R&D labs completed; five cGMP suites expected H1 2024.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Armata Pharmaceuticals, Inc. reported the three months and full fiscal year ended December 31, 2023 results: revenue approximately $1.5 million.

Period: the three months and full fiscal year ended December 31, 2023
Revenue: approximately $1.5 million
Result: reported results

Exact text from the filing

what we are poised to achieve this year and next,” Dr. Birx concluded. Fourth Quarter 2023 Financial Results Grant Revenue. The Company recognized grant revenue of approximately $1.5 million for the three months ended December 31, 2023, which represents Medical Technology Enterprise Consortium’s share of the costs incurred for the Company’s AP-SA02 program for the

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Armata Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-24-003704

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.